Published Date: 29 Jan 2025
Artificial intelligence is able to identify women who have an elevated risk of developing breast cancer several years before it is diagnosed, the Norwegian Institute of Public Health (FHI) said on Tuesday.
Read Full NewsAn investigative inhaled formulation of the psychedelic mebufotenin is linked to significant improvements in depression symptoms compared to placebo, a phase 2b trial shows.
A biological computer using human neurons learns Doom within 1 week, highlighting rapid adaptive learning and potential advantages over traditional AI systems.
The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.
Both drugs increase overall and progression-free survival.
1.
AI can identify women at risk of breast cancer years in advance: Study
2.
Early Esophageal Cancer pCR Rates Are Raised by Neoadjuvant PD-1 Blockade.
3.
An inoperable locally advanced NSCLC trial dubbed "Practice Changing".
4.
First-Line HCC Trial's Lenvatinib-Pembrolizumab Combo Misses Target.
5.
Antibody Drug-Conjugate Shows Promising Activity in Extensive-Stage SCLC
1.
Ethics of Experimental Oncology: Case Study on Autonomy, Consent & Decision-Making
2.
Beyond the Surface: Understanding the Silent Menace of Abdominal Hematomas
3.
Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients
4.
A Mural of Thrombus: Unlocking the Power of Art to Combat Cardiovascular Disease
5.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
3.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
5.
CDK4/6 Inhibitors in Extending Overall Survival in HR+/HER2- aBC Patients in Clinical Trial and Real World
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation